Fluvastatin, a 3-Hydroxy-3-Methylglutaryl Coenzyme A Reductase Inhibitor, Attenuates Left Ventricular Remodeling and Failure After Experimental Myocardial Infarction | Zendy

Shunji Hayashidani | Zendy; Hiroyuki Tsutsui | Zendy; Tetsuya Shiomi | Zendy; Nobuhiro Suematsu | Zendy; Shintaro Kinugawa | Zendy; Tomomi Ide | Zendy; Jing Wen | Zendy; Akira Takeshita | Zendy

Open Access

Fluvastatin, a 3-Hydroxy-3-Methylglutaryl Coenzyme A Reductase Inhibitor, Attenuates Left Ventricular Remodeling and Failure After Experimental Myocardial Infarction

Author(s) -

Shunji Hayashidani,

Hiroyuki Tsutsui,

Tetsuya Shiomi,

Nobuhiro Suematsu,

Shintaro Kinugawa,

Tomomi Ide,

Jing Wen,

Akira Takeshita

Publication year - 2002

Publication title -

circulation

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 7.795

H-Index - 607

eISSN - 1524-4539

pISSN - 0009-7322

DOI - 10.1161/hc0702.104164

Subject(s) - medicine , fluvastatin , cardiology , heart failure , myocardial infarction , ventricular remodeling , muscle hypertrophy , infarction , ejection fraction , endocrinology , simvastatin

Short-term administration of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors, statins, has been shown to attenuate ischemia-reperfusion injury. However, the effects of long-term administration of statins on left ventricular (LV) remodeling and failure after myocardial infarction remain unknown.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research

Address

John Eccles House
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom

About

About Careers Publisher Partners Contact Us Our institutional solutions Get Organisational Trial or Quote

Learn

FAQs Blog Terms of Use Privacy Policy

Download the Zendy App

Discover

Explore

Home ZAIA Blog